As a clinical-stage biotechnology company, Vera Therapeutics faced the critical challenge of clearly communicating complex scientific advancements to key audiences like investors, clinicians, and key opinion leaders. 

With their lead candidate, atacicept, for IgA nephropathy, new 96-week data from the ORIGIN trial had become available, and their understanding of its mechanism of action (MOA) had evolved. 

To effectively convey these crucial updates, we produced a series of updated videos. These compelling visual tools provided clear explanations of Atacicept's MOA and showcased the latest positive ORIGIN trial results. 

The completed videos have successfully supported Vera's marketing goals for atacicept by enhancing understanding and confidence among their target audiences, thereby aiding in securing investment, fostering stakeholder engagement, and educating the medical community about the drug's development.